Towards metabolically stable 5-HT7 receptor ligands: A study on 1-arylpiperazine derivatives and related isosters

Experimental Brain Research

Volumn 230, Issue 4, 2013, Pages 569-582

  Lacivita, Enza ^a   De Giorgio, Paola ^a   Patarnello, Daniela ^a   Niso, Mauro ^a   Colabufo, Nicola A ^a   Berardi, Francesco ^a   Perrone, Roberto ^a   Satala, Grzegorz ^b   Duszynska, Beata ^b   Bojarski, Andrzej J ^b   Leopoldo, Marcello ^a  

^a UNIVERSITY OF BARI   (Italy)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT7 receptors; Arylpiperazines; Microsomal S9 fraction; Serotonin

Indexed keywords

BUSPIRONE; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN METABOLISM;

ANIMALS; BIPHENYL COMPOUNDS; LIGANDS; PIPERAZINES; PIPERIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SEROTONIN; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885608428     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-013-3498-0     Document Type: Article

References (55)

1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009) Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 205:119-128
2. Bantle GW, Elworthy TR, Guzman A, Jaime-Figueroa S, Lopez-Tapia FJ, Morgans Jr. DJ, Perez-Medrano A, Pfister JR, Sjogren EB, Talamas FX (1996) Eur Pat Appl EP 0748800 [Chem Abstr 126:131468 (1996)]
3. Bojarski AJ, Cegla MT, Charakchieva-Minol S, Mokrosz MJ, Mackowiak M, Misztal S, Mokrosz JL (1993) Structure-activity relationship studies of CNS agents. Part 9: 5-HT1A and 5-HT2 receptor affinity of some 2- and 3-substituted 1,2,3,4-tetrahydro-beta-carbolines. Pharmazie 48:289-294
4. Bonaventure P, Dugovic C, Kramer M, De Boer P, Singh J, Wilson S, Bertelsen K, Di J, Shelton J, Aluisio L, Dvorak L, Fraser I, Lord B, Nepomuceno D, Ahnaou A, Drinkenburg W, Chai W, Dvorak C, Carruthers N, Sands S, Lovenberg T (2012) Translational evaluation of JNJ-18038683, a 5-HT7 receptor antagonist, on REM sleep and in major depressive disorder. J Pharmacol Exp Ther 342:429-440
5. Brenchat A, Romero L, Garcia M, Pujol M, Burgueno J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM (2009) 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. Pain 141:239-247
6. Buchanan JL, Bregman H, Chakka N, Dimauro EF, Du B, Nguyen HN, Zheng XM (2010) PCT Int Appl WO 2010022055 [Chem Abstr 152:311635 (2010)]
7. Caccia S (2007) N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 8:612-622
8. Chen L, Cheung AW-H, Chu X-J, Danho W, Swistok J, Yagaloff KA (2001) PCT Int Appl WO 2001074844 [Chem Abstr 135:304143 (2001)]
9. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
10. Citrome L (2011) Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med 123:153-162
11. Costa L, Spatuzza M, D'Antoni S, Bonaccorso CM, Trovato C, Musumeci SA, Leopoldo M, Lacivita E, Catania MV, Ciranna L (2012) Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol Psychiatry 72:924-933
12. Elworthy TR, Ford AP, Bantle GW, Morgans DJ Jr, Ozer RS, Palmer WS, Repke DB, Romero M, Sandoval L, Sjogren EB, Talamás FX, Vazquez A, Wu H, Arredondo NF, Blue DR Jr, DeSousa A, Gross LM, Kava MS, Lesnick JD, Vimont RL, Williams TJ, Zhu QM, Pfister JR, Clarke DE (1997) N-arylpiperazinyl-N'- propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists. J Med Chem 40:2674-2687
13. Forbes IT, Douglas S, Gribble AD, Ife RJ, Lightfoot AP, Garner AE, Riley GJ, Jeffrey P, Stevens AJ, Stean TO, Thomas DR (2002) SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties. Bioorg Med Chem Lett 12:3341-3344
14. Geneste H, Backfisch G, Braje W, Delzer J, Haupt A, Hutchins CW, King LL, Kling A, Teschendorf HJ, Unger L, Wernet W (2006) Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett 16:490-494
15. Guscott M, Bristow LJ, Hadingham K, Rosahl TW, Beer MS, Stanton JA, Bromidge F, Owens AP, Huscroft I, Myers J, Rupniak NM, Patel S, Whiting PJ, Hutson PH, Fone KC, Biello SM, Kulagowski JJ, McAllister G (2005) Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 48:492-502
16. Harte SE, Kender RG, Borszcz GS (2005) Activation of 5-HT1A and 5-HT7 receptors in the parafascicular nucleus suppresses the affective reaction of rats to noxious stimulation. Pain 113:405-415
17. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG (2005) 5-HT7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol Psychiatry 58:831-837
18. Hedlund PB, Leopoldo M, Caccia S, Sarkisyan G, Fracasso C, Martelli G, Lacivita E, Berardi F, Perrone R (2010) LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor. Neurosci Lett 481:12-16
19. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994) International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46:157-203
20. Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533-554
21. Jacobs R, Shenvi A (1994) Eur Pat Appl EP 630887 [Chem Abstr 122:187403 (1995)]
22. Jia L, Liu X (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8:822-829
23. Kikuchi C, Ando T, Watanabe T, Nagaso H, Okuno M, Hiranuma T, Koyama M (2002) 2a-[4-(Tetrahydropyridoindol-2-yl)butyl]tetrahydrobenzindole derivatives: new selective antagonists of the 5-hydroxytryptamine7 receptor. J Med Chem 45:2197-2206
24. Kimura T, Katsube T, Nishigaki T (1996) PCT Int Appl WO 9602512 [Chem Abstr 125:10854 (1996)]
25. Kvachnina E, Liu G, Dityatev A, Renner U, Dumuis A, Richter DW, Dityateva G, Schachner M, Voyno-Yasenetskaya TA, Ponimaskin EG (2005) 5-HT7 receptor is coupled to Ga-subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J Neurosci 25:7821-7830
26. Lacivita E, Patarnello D, Stroth N, Caroli A, Niso M, Contino M, De Giorgio P, Di Pilato P, Colabufo NA, Berardi F, Perrone R, Svenningsson P, Hedlund PB, Leopoldo M (2012) Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo. J Med Chem 55:6375-6380
27. Leo D, Adriani W, Cavaliere C, Cirillo G, Marco EM, Romano E, di Porzio U, Papa M, Perrone-Capano C, Laviola G (2009) Methylphenidate to adolescent rats drives enduring changes of accumbal Htr7 expression: implications for impulsive behavior and neuronal morphology. Genes Brain Behav 8:356-368
28. Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V (2004a) Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J Med Chem 47:6616-6624
29. Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Perrone R, Tortorella V (2004b) Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors. J Pharm Pharmacol 56:247-255
30. Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R (2007) Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen- 1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem 50:4214-4221
31. Leopoldo M, Lacivita E, De Giorgio P, Fracasso C, Guzzetti S, Caccia S, Contino M, Colabufo NA, Berardi F, Perrone R (2008) Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J Med Chem 51:5813-5822
32. Leopoldo M, Lacivita E, Berardi F, Perrone R, Hedlund PB (2012) Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther 129:120-148
33. Luo G, Mattson GK, Bruce MA, Wong H, Murphy BJ, Longhi D, Antal-Zimanyi I, Poindexter GS (2004) Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg Med Chem Lett 14:5975-5978
34. Mannhold R (2006) Lipophilicity: its calculation and application in ADMET predictions. In: Testa B, Turski L (eds) Virtual ADMET assessment in target selection and maturation. IOS Press, Amsterdam, pp 43-66
35. Martin GE, Elgin RJ Jr, Mathiasen JR, Davis CB, Kesslick JM, Baldy WJ, Shank RP, DiStefano DL, Fedde CL, Scott MK (1989) Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem 32:1052-1056
36. Medina RA, Sallander J, Benhamú B, Porras E, Campillo M, Pardo L, López-Rodríguez ML (2009) Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem 52:2384-2392
37. Miao Z, Kamel A, Prakash C (2005) Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. Drug Metab Dispos 33:879-883
38. Nagel AA (1990) Eur Pat Appl EP 372776 [Chem Abstr 113:211852 (1990)]
39. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70:829-836
40. Natsui K, Mizuno Y, Tani N, Yabuki M, Komuro S (2007) Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes. Eur J Drug Metab Pharmacokinet 32:233-240
41. Paillet-Loilier M, Fabis F, Lepailleur A, Bureau R, Butt-Gueulle S, Dauphin F, Lesnard A, Delarue C, Vaudry H, Rault S (2007) Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett 17:3018-3022
42. Paluchowska MH, Bugno R, Duszynska B, Tatarczynska E, Nikiforuk A, Lenda T, Chojnacka-Wojcik E (2007) The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines. Bioorg Med Chem 15:7116-7125
43. Patane MA, Bock MG, Newton RC (1998) PCT Int Appl WO 9857638 [Chem Abstr 130:81519 (1999)]
44. Pittala V, Pittala D (2011) Latest advances towards the discovery of 5-HT(7) receptor ligands. Mini Rev Med Chem 11:1108-1121
45. Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (2007) 5-HT7 receptor ligands: recent developments and potential therapeutic applications. Mini Rev Med Chem 7:945-960
46. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D (2000) Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 49(Suppl 1):35S-42S
47. Raubo P, Beer MS, Hunt PA, Huscroft IT, London C, Stanton JA, Kulagowski JJ (2006) Aminoalkyl phenyl sulfones-a novel series of 5-HT7 receptor ligands. Bioorg Med Chem Lett 16:1255-1258
48. Reese CB, Thompson EA (1988) A new synthesis of 1-arylpiperidin-4-ols. J Chem Soc Perkin Trans 1:2881-2885
49. Sarkisyan G, Roberts AJ, Hedlund PB (2010) The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 209:99-108
50. Speranza L, Chambery A, Di Domenico M, Crispino M, Severino V, Volpicelli F, Leopoldo M, Bellenchi GC, di Porzio U, Perrone-Capano C (2013) The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways. Neuropharmacology 67:155-167
51. Spooren W, Lindemann L, Ghosh A, Santarelli L (2012) Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. Trends Pharmacol Sci 33:669-684
52. Volk B, Barkoczy J, Hegedus E, Udvari S, Gacsalyi I, Mezei T, Pallagi K, Kompagne H, Levay G, Egyed A, Harsing LG Jr, Spedding M, Simig G (2008) (Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists. J Med Chem 51:2522-2532
53. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E (2006) Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51:578-586
54. Wu W-N, McKown LA (2007) Hepatic in vitro metabolism of etoperidone, an antidepressant drug, in the rat and human. Taiwan Pharm J 59:31-38
55. Zajdel P, Marciniec K, Maślankiewicz A, Paluchowska MH, Satała G, Partyka A, Jastrzeobska-Wieosek M, Wróbel D, Wesołowska A, Duszyńska B, Bojarski AJ, Pawłowski M (2011) Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands. Bioorg Med Chem 15:6750-6759